Advertisements


vTv Therapeutics Fails Late-Stage Alzheimer"s Study; Is There A Chance For A Comeback?

vTv Therapeutics Fails Late-Stage Alzheimer"s Study; Is There A Chance For A Comeback?.....»»

Category: topSource: seekingalphaApr 16th, 2018

Stifel Sees Challenging Road Ahead For vTv Therapeutics After Failed Alzheimer"s Trial

vTv Therapeutics Inc (NASDAQ: VTVT) announced Monday after the close that results from Part A of its late-stage study of an investigational medication to treat Alzheimer's disease did not m Latest Ratings for VTVT D.....»»

Category: blogSource: benzingaApr 10th, 2018

Edge Therapeutics Loses Edge on Failure of Late-Stage Study

Edge Therapeutics (.....»»

Category: dealsSource: nytApr 2nd, 2018

Edge Therapeutics Loses Edge on Failure of Late-Stage Study

Zacks.....»»

Category: topSource: redinewsApr 2nd, 2018

Merck (MRK) Halts Another Late Stage Study on Alzheimer"s

Merck (MRK) stalls a phase III study evaluating verubecestat for the treatment of prodromal Alzheimer's disease on the recommendation of an .....»»

Category: smallbizSource: nytFeb 14th, 2018

UPDATE: Axovant shares tumble 71% after late-stage trial of Alzheimer"s treatment fails to meet primary goals

Axovant Sciences Ltd. shares cratered 71% in premarket trade Tuesday, after the company said a late-stage trial of a.....»»

Category: topSource: marketwatchSep 26th, 2017

Down 13.69%: Is Sage Therapeutics Stock a Bad-News Buy?

Sage's lead drug candidate whiffs in a late-stage study......»»

Category: topSource: foxnewsSep 12th, 2017

Sage Therapeutics Gets a Dunce Hat

Sage Therapeutics saw its shares drop by about a quarter early on Tuesday after the firm gave an update on its late-stage study trial in the treatment super-refractory status epilepticus......»»

Category: blogSource: 247wallstSep 12th, 2017

Ultragenyx shares drop as muscle-disease drug study fails

Ultragenyx Pharmaceutical Inc. shares fell in the extended session Tuesday after the biotech company said a late-stage clinical trial for its severe muscle dis.....»»

Category: topSource: marketwatchAug 22nd, 2017

Ultragenyx Shares Drop As Muscle-disease Drug Study Fails

Ultragenyx Pharmaceutical Inc. shares fell in the extended session Tuesday after the biotech company said a late-stage clinical trial for its severe muscle disease treatment did not reach its goals......»»

Category: topSource: foxnewsAug 22nd, 2017

Celldex"s Phase II Breast Cancer Study Fails, Shares Plunge

Celldex Therapeutics' (CLDX) glembatumumab vedotin fails to meet primary endpoint in phase IIb METRIC study in metastat.....»»

Category: smallbizSource: nytApr 17th, 2018

Shares of vTv Therapeutics plummet as Alzheimer"s study disappoints

Shares of vTv Therapeutics Inc. plunged in the exte.....»»

Category: topSource: marketwatchApr 9th, 2018

Incyte, Merck Fall on Failed Late-Stage Study

The skin cancer treatment did not meet primary objectivesRelated Stocks: INCY, MRK,.....»»

Category: dealsSource: nytApr 6th, 2018

Your Daily Pharma Scoop: Conatus Setback, Applied DNA Signs Agreement, Evolus Announces Results From Late-Stage Study

Your Daily Pharma Scoop: Conatus Setback, Applied DNA Signs Agreement, Evolus Announces Results From Late-Stage Study.....»»

Category: topSource: seekingalphaApr 6th, 2018

Incyte stock plummets following disappointed clinical study results

Incyte Corp.’s stock price plunged nearly 20 percent Friday after the Wilmington biotechnology company announced disappointing late-stage study results for an experimental cancer therapy. The results from a phase-III clinical study, testing Inc.....»»

Category: topSource: bizjournalsApr 6th, 2018

Why Edge Therapeutics Fell Off the Edge of the Earth

Edge Therapeutics saw its shares plunge massively following the results from a late-stage trial......»»

Category: blogSource: 247wallstMar 28th, 2018

Edge Therapeutics"s stock plummets on heavy volume after late-stage drug trial discontinued

Shares of Edge The.....»»

Category: topSource: marketwatchMar 28th, 2018

Esperion Nets Another Positive Late-Stage Study Under Its Belt

Esperion Nets Another Positive Late-Stage Study Under Its Belt.....»»

Category: topSource: seekingalphaMar 28th, 2018

Portola Pharma (PTLA) Announces New Interim Data From Late-Stage Study Of AndexXa - Slideshow

Portola Pharma (PTLA) Announces New Interim Data From Late-Stage Study Of AndexXa - Slideshow.....»»

Category: topSource: seekingalphaMar 13th, 2018

Is Anthera Dead in the Water?

Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) saw its shares get absolutely crushed in Monday’s session following missed results in a late-stage study. Specifically, the company said that Sollpura did........»»

Category: blogSource: 247wallstMar 12th, 2018

Your Daily Pharma Scoop: Genocea Surges, Gilead"s Biktarvy, GlaxoSmithKline"s Vaccine Succeeds In Late-Stage Study

Your Daily Pharma Scoop: Genocea Surges, Gilead"s Biktarvy, GlaxoSmithKline"s Vaccine Succeeds In Late-Stage Study.....»»

Category: topSource: seekingalphaMar 7th, 2018